The global anti-viral drug market is expected to be worth $59,596.8 million in 2022. Throughout the forecast period, the introduction of generic antiviral medicines, as well as increased awareness about the availability of various vaccines for viral infections, are affecting growth. The overall demand for Anti-Viral Drugs is expected to grow at a CAGR of 3.9% between 2022 and 2032, reaching around US$ 87,675.36 Million.

Anti-viral medications are medications that are used to treat viral infections. Unlike antibiotics, most anti-viral drugs are used to treat specific viral infections, whereas a broad-spectrum anti-viral drug is effective against a wide range of viruses. Antiviral drugs do not kill the pathogens they target; rather, they inhibit their growth.

Because of increased awareness, an increase in diseased population, and the introduction of new drugs with improved efficacy, the global anti-viral drugs market is expected to grow at a moderate rate in the pharmaceutical market.

Several major patents will expire during the forecast period, including Combivir, Sustiva, Tenofovir, Tamiflu, Relenza, and Telbivudine. The patent expirations of these blockbuster drugs are expected to increase competition in the antivirals therapeutics market.

Late-stage pipeline drugs are expected to enter the market, which will have a positive impact on the market. Because most antivirals are considered relatively harmless to the host, they are used to treat infections. They are not medications, but they can destroy or deactivate virus particles both outside and inside the body.

Patients with herpes viruses, HIV, influenza A and B viruses, and hepatitis B and C viruses are treated with antiviral drugs.

Anti-viral Drugs Market: Key Players

Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

Browse More@

Key Segments Covered in the Anti-Viral Drugs Industry Analysis

Anti-Viral Drugs Market by Product type:

  • Hepatitis-C antivirals
  • HIV antivirals
  • Herpes antivirals
  • Hepatitis-B antivirals
  • Influenza antivirals
  • Others (Pneumonia, Flu, etc.)

Anti-Viral Drugs Market by End-user:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers